Published on October 09, 2018<\/p>\r\n\r\n\r\n\r\n
CONTACT INFORMATION<\/strong> MONMOUTH JUNCTION, NJ, October 10, 2018 \/ PRNewswire\/ – Tris Pharma, Inc. (Tris), a\u00a0 pharmaceutical company focused on developing innovative technology-based therapeutic products that address unmet patient needs, today announced the appointment of Thomas Curatolo as Chief Commercial Officer to lead Tris\u2019 expanded Attention Deficit Hyperactivity Disorder (ADHD) portfolio.<\/p>\r\n\r\n\r\n\r\n Mr. Curatolo has more than 20 years of commercial brand leadership experience with large, medium and start-up pharmaceutical companies. During his career, he has held positions of increasing responsibility in sales, marketing, strategy and sales operations. He has spent most of the last 2 decades working on or leading ADHD brands, including two of the only three blockbuster products in the category. He spent 10 years at Shire Pharmaceuticals, preceded by 10 years at Johnson & Johnson. He holds an M.B.A. in Marketing Management from St. John\u2019s University and a B.A. in Environmental Economics from Rutgers University.<\/p>\r\n\r\n\r\n\r\n \u201cTom\u2019s track record, especially within the ADHD category, coupled with his extensive experience in pharmaceutical sales, sales management and marketing, makes him an ideal leader for our expanded ADHD business,\u201d said Ketan Mehta, Founder and Chief Executive Officer of Tris. \u201cAlong with Barry Herman, M.D., M.M.M., Tris\u2019 Chief Medical Officer, who is building a world-class Medical Affairs team, we are poised to become a leading ADHD Company.\u201d<\/p>\r\n\r\n\r\n\r\n \u201cI am honored to have the opportunity to lead Tris\u2019 commercial organization, and recognize that with our recent acquisition, we are now positioned to establish Tris as a leader in the ADHD category,\u201d said Mr. Curatolo. \u201cI look forward to working with my colleagues at Tris to help improve the lives of patients we serve.\u201d<\/p>\r\n\r\n\r\n\r\n
FOR INFORMATION
Peter Ciano (732) 823-4950
pciano@trispharma.com<\/p>\r\n\r\n\r\n\r\n